Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer

Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer

Abstract Background Resistance to tamoxifen (TAM) frequently occurs in the treatment of estrogen receptor positive (ER+) breast cancer. Accumulating evidences indicate that transcription factor HOXB13 is of great significance in TAM resistance. However, the regulation of HOXB13 in TAM-resistant brea...

Full description

Bibliographic Details
Main Authors: Bowen Liu, Tianjiao Wang, Huawei Wang, Lu Zhang, Feifei Xu, Runping Fang, Leilei Li, Xiaoli Cai, Yue Wu, Weiying Zhang, Lihong Ye
Format: Article
Language:English
Published: BMC 2018-02-01
Series:Journal of Hematology & Oncology
Subjects:
Breast cancer
Tamoxifen resistance
HBXIP
HOXB13
Acetylation
Chaperone-mediated autophagy
Online Access:http://link.springer.com/article/10.1186/s13045-018-0577-5

Internet

http://link.springer.com/article/10.1186/s13045-018-0577-5

Similar Items